Sean Smith’s Post

The liver, a complex organ, is prone to various issues if not cared for. Genetic factors, lifestyle choices like excessive alcohol, medication, and viral infections can lead to liver diseases. Chronic inflammation can progress to conditions like cirrhosis or fibrosis. Organ transplantation is often the only solution for end-stage liver failure or cancer. However, this option is limited by the scarcity of donors, surgical risks, immunological complications like graft-versus-host syndrome, and high medical costs. Find how Mesenchymal Stem Cell is potential treatment at our article https://lnkd.in/guZrZDyt #liver #livertreatment #livertheraphy #stemcelltherapy #stemcelltreatment #regenerativemedicine #aestheticmedicine #celltherapy #longevity #livelong #ageless #antiwrinkle #dermatologist #medicalaesthetics #dermatology #aestheticdoctor #cosmeticdoctor #luxurycosmetics #crazyrichasians #medicaldoctor #beautyclinic #skinclinic #luxurycosmetic #luxuryhealth

Prurigo nodularis (also known as chronic prurigo) is a severe dermatologic disease that can have long lasting consequences in patients: persistent and quite disturbing itch, poor sleep quality, higher likelihood of mental comorbidities, just to mention a few. I was fortunate to participate as a Principal Investigator in the dupilumab Phase 3 program for the treatment of prurigo nodularis and as a co-author in the publication that aggregates the data from both PRIME and PRIME-2 trials. This article has just been published in JAAD Int. You will find below the link for the full article in open access. https://lnkd.in/dfRfNFnv Safe and effective treatment options bring hope to a disease that many in the past have considered a lost cause. 🤲 It's very exciting to be working among great dermatologists who are contributing everyday to the scientific development of knowledge regarding itch, like Sonja Ständer 💡 Brian S. Kim 💡 Gil Yosipovitch 💡 Shawn Kwatra 💡 #prurigo #itch #dermatology #immunology #prurigonodularis #clinicaltrials

Imagine integrating genetic testing and a comprehensive drug efficacy panel into your treatment plans. 🧬 Imagine detailed reports with recommended compounds based on efficacy levels. 💊 Imagine the transformative impact on your treatment outcomes. 🚀 Join our webinar to learn about this revolutionary approach through clinical cases. 🌟 #genetictesting #personalizedmedicine

🎉 A Breakthrough in Treating Deadly Skin Disease: World-First Cure Achieved! In an incredible leap forward for medical science, researchers have successfully cured patients suffering from Toxic Epidermal Necrolysis (TEN), a rare and often fatal skin condition, through an innovative use of existing drugs. Published in Nature, this landmark study could pave the way for an approved curative therapy, offering hope where there was previously very little. 🔬 Study Highlights: ◾ TEN, characterized by severe skin blistering and a high mortality rate, was halted using JAK inhibitors, drugs already used for inflammatory diseases. ◾ The study not only saved lives but also opened new doors in the treatment of other severe skin disorders and inflammatory conditions. 🌍 Global Impact: This pioneering work represents a monumental step in dermatology and emergency medicine, showcasing the power of collaborative research and the repurposing of drugs to fast-track life-saving treatments. 🔗 https://lnkd.in/grttG9-Q #MedicalResearch #Dermatology #HealthcareInnovation #SkinDisease #LifeSavingResearch

Congratulations to Jannik Rousel, for successfully defending his PhD thesis on October 24, 2024! Jannik’s research introduces non-invasive technologies to enhance early clinical trials for chronic skin diseases like dermatitis and psoriasis. Chronic skin diseases impact 20% of the global population while treatments remain insufficient. His thesis demonstrates data-driven methods that improve decision-making in drug development, including advanced diagnostic tools in a dermatitis trial, increased confidence in clinical outcomes, and the identification of ceramides as a key biomarker for skin barrier health. Well done, Jannik, on this contribution to advancing skin disease research and advancements in early clinical decision-making!  Find his thesis here: https://lnkd.in/ezkrhm9Z #PhDDefense #dermatology #Skindiseases #ClinicalResearch 

In honor of Eczema Awareness Month, we’re spotlighting atopic dermatitis (AD) and new advancements in its management. 💡 Our latest CME activity, A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches, led by Dr. Peter Lio and Dr. Lisa Swanson, dives into the latest clinical data on current and emerging AD therapies. This educational session also covers strategies for treatment selection, long-term disease control, and overcoming treatment challenges. Learning Objectives: 1️⃣ Critically evaluate clinical data and mechanisms of AD therapies 2️⃣ Identify and overcome challenges in topical AD treatments 3️⃣ Develop individualized topical therapy strategies for AD patients 🔗Advance your AD expertise here: https://lnkd.in/eFZDCf2J #EczemaAwarenessMonth #AtopicDermatitis #AD #Eczema #CME #CE #Dermatology #LiVDerm

We were interested to read in a recent JAMA research letter that following a first #melanoma diagnosis, patients have an almost 9-fold increased risk of developing another primary melanoma compared with the general population. The authors go on to explain that this risk varies across racial and ethnic groups but the highest absolute risk was found in the white population. They conclude that further work is needed to guide population-level monitoring in the future. https://bit.ly/4dTlmIu   Our prognostic test #AMBLor identifies early-stage melanomas that are at low risk of progression. Stratifying patients into low-risk or at-risk means that any further diagnostic procedures and follow-up schedules can be personalised, potentially saving time, resources and helping to alleviate patient anxiety. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers 

Under the motto “Uncovering the Broad Spectrum of Psoriatic Disease” the 7th World Psoriasis & Psoriatic Arthritis Conference took place last week in Stockholm. The focus of the conference is to improve the lives of patients living with psoriatic disease by sharing significant achievements in the prevention, diagnosis, and treatment. With PsorX-LabDisk, we support dermatopathologists in the differential diagnosis of psoriasis and eczema - as there are still up to 50% misdiagnoses of the two skin diseases due to overlapping clinical and histological appearances. However, the feedback from the dermatologists at the conference was clear: ❗This is not enough❗The test needs to be introduced into dermatologists' practices for use at the point of care. How good that work on it is already in full swing in the Dermagnostix R&D team!💪🚀 This feedback once again reinforces our belief in the urgent need for molecular diagnostics for inflammatory skin diseases - both for dermatologists and pathologists. 💡You want to be part of the #DermagnosticFuture? Schedule a meeting with us now to learn more about PsorX: https://lnkd.in/egn75BGc #MolecularDiagnostics #Psoriasis #PsorX #Dermatology #Innovation #IFPA

We recently we had the great pleasure of meeting with some of the world’s leading experts in the fields of #Dermatology and #AtopicDermatitis, to discuss clinical development plans for the lead candidate in our pipeline of disease-modifying #Therapies for chronic #Autoimmune and #InflammatoryDiseases. SYX-5219, which will advance into the clinic for the treatment of atopic dermatitis, targets a critical enzyme regulating cell #Metabolism called pyruvate kinase M2 (PKM2) – a novel therapeutic target with the potential to rebalance the #ImmuneSystem, normalize immune cell function and drive sustained disease remission.    As we finalise our development plans for this candidate, it’s vital that we collaborate with, and learn from, those who are expert in the field and those who are treating patients today. A huge thank you to everyone who shared their time, knowledge, insights and real-world experiences – invaluable to us in ensuring our #Science can continue to progress at pace for the benefit of patients.   Find out more about the latest progress within Sitryx’s proprietary pipeline: https://lnkd.in/eS8FGNRx

Just published on the Journal of Dermatological Treatment! "Clinical course and disease burden of patients with generalized pustular psoriasis in Portugal: a multicenter retrospective cohort study". In this multicenter study, coordinated by the Portuguese Group of Psoriasis, we evaluated the clinical characteristics, triggering factors, morbidity, disease progression and treatment response in patients diagnosed with GPP in Portugal. Our analysis highlights the chronic, heterogeneous, and debilitating nature of GPP, associated with multiple flares, leading to hospitalizations and emergency department visits, significantly compromising the quality of life and survival of patients. Moreover, standard treatment options often fail to achieve adequate disease control. #GPP #Dermatology #Portugal